[1] |
Li G,Zhang Y,Ma H,et al. Arm port vs chest port:a systematic review and meta-analysis [J]. Cancer Manag Res,2019,11:6099-6112.
|
[2] |
Sung H,Ferlay J,Siegel RL,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin,2021,71(3):209-249.
|
[3] |
邵志敏,江泽飞,李俊杰,等. 中国乳腺癌新辅助治疗专家共识(2019年版) [J]. 中国癌症杂志,2019,29(5):390-400.
|
[4] |
Xu H,Chen R,Jiang C,et al. Implanting totally implantable venous access ports in the upper arm is feasible and safe for patients with early breast cancer [J]. J Vasc Access,2020,21(5):609-614.
|
[5] |
Burbridge B,Chan IYM,Bryce R,et al. Satisfaction and quality of life related to chemotherapy with an arm port:a pilot study [J]. Can Assoc Radiol J,2016,67(3):290-297.
|
[6] |
Goltz JP,Noack C,Petritsch B,et al. Totally implantable venous power ports of the forearm and the chest:initial clinical experience with port devices approved for high-pressure injections [J]. Br J Radiol,2012,85(1019):e966-e972.
|
[7] |
李玉彬,胡一波. 头静脉与贵要静脉的应用解剖和PICC置管 [J]. 医学理论与实践,2011,24(24):3027-3029.
|
[8] |
Shiono M,Takahashi S,Kakudo Y,et al. Upper arm central venous port implantation:a 6-year single institutional retrospective analysis and pictorial essay of procedures for insertion [J]. PLoS One,2014,9(3):e91335.
|
[9] |
马力,刘运江,刘荫华. 中国乳腺癌中心静脉血管通路临床实践指南(2022版) [J]. 中国实用外科杂志,2022,42(2):151-158.
|
[10] |
刘春丽,孟爱凤,施如春,等. 乳腺癌患者上臂输液港植入方式改进 [J]. 护理学杂志,2019,34(15):47-49.
|
[11] |
中心静脉血管通路装置安全管理专家组. 中心静脉血管通路装置安全管理专家共识(2019版) [J]. 中华外科杂志,2020,58(4):261-272.
|
[12] |
Ma L,Ge ZC,Xin L,et al. Clinical practice guidelines for breast cancer implantable intravenous infusion ports:Chinese Society of Breast Surgery practice guidelines 2021 [J]. Chin Med J,2021,134(16):1894-1896.
|
[13] |
付攸缘,谢晓燕,丁玲,等. 乳腺癌化疗患者两种臂式输液港植入方式效果比较 [J]. 护理学杂志,2022,37(11):43-45,70.
|
[14] |
王玲,刘晓岭,郝璐,等. 腔内心电图定位在乳腺癌化疗病人上臂植入式输液港中的应用 [J]. 临床外科杂志,2017,25(12):936-938.
|
[15] |
胡丽娟,崔璀,吴钢,等. 不同方式腔内心电图定位技术在经上臂静脉植入输液港中的应用研究 [J]. 中华护理杂志,2019,54(3):443-446.
|
[16] |
张元红,曹苏生,牛东东,等. 乳腺癌患者上臂植入式静脉输液港相关并发症的护理研究 [J]. 世界最新医学信息文摘,2019,19(30):22-23,25.
|
[17] |
Mori Y,Nagayama S,Kawamura J,et al. A retrospective analysis on the utility and complications of upper arm ports in 433 cases at a single institute [J]. Int J Clin Oncol,2016,21(3):474-482.
|
[18] |
Ji L,Yang J,Miao J,et al. Infections related to totally implantable venous-access ports:long-term experience in one center [J]. Cell Biochem Biophys,2015,72(1):235-240.
|
[19] |
高姗,林江,李福琴,等. 完全植入式静脉输液港相关感染的危险因素 [J]. 中国感染控制杂志,2018,17(9):815-818.
|
[20] |
仇晓霞,金光鑫,郭艳,等. 肿瘤患者上臂植入输液港相关感染发生率及危险因素研究 [J]. 上海交通大学学报(医学版),2019,39(10):1183-1187.
|
[21] |
符丹丽,陈培丰. 恶性肿瘤高凝状态的中西医发病机制 [J]. 肿瘤防治研究,2018,45(3):179-182.
|
[22] |
王翔,张雨洁. 恶性肿瘤患者凝血功能异常的研究进展 [J]. 现代肿瘤医学,2016,24(8):1325-1328.
|
[23] |
王静,张侠. 恶性肿瘤患者高凝状态的危险因素、发生机制及实验室检测 [J]. 检验医学与临床,2015,12(15):2284-2287.
|
[24] |
Wildgruber M,Lueg C,Borgmeyer S,et al. Polyurethane versus silicone catheters for central venous port devices implanted at the forearm [J]. Eur J Cancer,2016,59:113-124.
|
[25] |
Busch JD,Vens M,Mahler C,et al. Complication rates observed in silicone and polyurethane catheters of totally implanted central venous access devices implanted in the upper arm [J]. J Vasc Interv Radiol,2017,28(8):1177-1183.
|
[26] |
Spencer TR,Mahoney KJ. Reducing catheter-related thrombosis using a risk reduction tool centered on catheter to vessel ratio [J]. J Thromb Thrombolysis,2017,44(4):427-434.
|
[27] |
Makary MS,Lionberg A,Khayat M,et al. Advanced stage breast cancer is associated with catheter-tip thrombus formation following implantable central venous port placement [J]. Phlebology,2019,34(2):107-114.
|
[28] |
Tippit D,Siegel E,Ochoa D,et al. Upper-extremity deep vein thrombosis in patients with breast cancer with chest versus arm central venous port catheters [J]. Breast Cancer Basic Clin Res,2018,12:1178223418771909.
|
[29] |
Liu Y,Li L,Xu L,et al. Comparisonbetween arm port and chest port for optimal vascular access port in patients with breast cancer:a systematic review and meta-analysis [J]. BioMed Res Int,2020,2020(1):9082924.
|
[30] |
陈莉,罗凤,邢雷,等. 乳腺癌化疗患者输液港导管周围附壁血栓形成的探讨 [J]. 上海交通大学学报(医学版),2017,37(4):514-517.
|
[31] |
武中林,刘玉芝,王建新,等. 数字减影血管造影在植入式静脉输液港体内导管纤维蛋白鞘形成中的应用价值 [J]. 中国全科医学,2016,19(3):356-358,363.
|
[32] |
凌泉,陈勇,李斌飞,等. 植入式静脉输液港体内导管纤维蛋白鞘形成的诊断及处理方法 [J]. 中国医学创新,2017,14(27):142-144.
|
[33] |
王建新,武中林,苏金娜,等. 植入式静脉港体内导管纤维蛋白鞘形成的诊断及处理 [J]. 河北医科大学学报,2016,37(9):1047-1050.
|
[34] |
汪洋,武佩佩. 肿瘤患者应用植入式静脉输液港导管堵塞的研究现状 [J]. 护士进修杂志,2017,32(3):229-232.
|
[35] |
陈湘威,陈妙霞,林金香,等. 恶性肿瘤病人上臂植入式输液港与PICC的效果比较 [J]. 全科护理,2019,17(33):4109-4113.
|
[36] |
刘瑞娟. 上臂植入式输液港与上臂PICC在肿瘤化疗患者中的应用研究[J/CD]. 临床医药文献电子杂志,2020,7(21):28.
|
[37] |
陈丽珽. 肿瘤患者上臂完全植入式静脉输液港应用效果观察 [J]. 医学理论与实践,2021,34(18):3265-3267.
|
[38] |
吴惠莲,施丽华,何兰兰. 上臂植入式输液港与上臂PICC在肿瘤化疗患者中的应用效果比较 [J]. 当代护士(下旬刊),2018,25(10):102-105.
|
[39] |
岳鑫. 上臂植入式输液港与上臂PICC应用价值对比分析 [J/CD]. 临床医药文献电子杂志,2020,7(1):79,100.
|
[40] |
李金丽,郭利斌. 少数民族地区上臂植入式输液港与上臂PICC应用效果的调查分析 [J]. 内蒙古医科大学学报,2019,41(2):311-314.
|
[41] |
郭敏,康丽君,陈雪梅,等. 上臂植入式输液港与上臂PICC应用效果比较 [J]. 护理实践与研究,2016,13(11):125-127.
|
[42] |
Yang SS,Ahn MS. A comparison between upper arm and chest for optimal site of totally implanted venous access ports in patients with female breast cancer [J]. Ann Vasc Surg,2018,50:128-134.
|
[43] |
王影新,刘飞,赵璇,等. 乳腺癌化疗患者不同部位植入输液港的对比研究 [J]. 中华护理杂志,2019,54(6):917-921.
|
[44] |
张园园,乔志瑶. 上臂输液港与胸壁输液港在肿瘤患者中的应用比较 [J/CD]. 国际感染病学(电子版),2020,9(3):122-123.
|
[45] |
徐春兰,曹霞,杨静姣,等. 上臂式静脉输液港与胸壁式静脉输液港临床应用研究 [J]. 护士进修杂志,2018,33(5):474-476.
|
[46] |
张文静,颜欣,田红梅. 上臂式静脉输液港与胸壁式静脉输液港比较 [J]. 中国卫生标准管理,2020,11(6):146-148.
|
[47] |
程洁茵,陈锦娇. 超声引导下上臂植入式输液港在接受化疗的乳腺癌患者输液中的应用价值 [J]. 当代医药论丛,2020,18(10):243-244.
|
[48] |
吴孝红,陈惜遂,张红,等. 三种路径植入静脉输液港安全性的Meta分析 [J]. 中华护理杂志,2019,54(10):1551-1558.
|
[49] |
Voci A,Lee D,Ho E,et al. Impact of port site scar on perception of patients with breast cancer:patient-reported outcomes [J]. Breast Cancer Res Treat,2018,170:569-572.
|
[50] |
周腊梅,曹雯,李丽丽,等. 乳腺癌化疗患者在B超引导下经上臂植入静脉输液港的应用效果及护理措施 [J]. 健康女性,2021(31):36.
|
[51] |
Fang S,Yang J,Song L,et al. Comparison of three types of central venous catheters in patients with malignant tumor receiving chemotherapy [J]. Patient Prefer Adherence,2017,11:1197-1204.
|